A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition.


Journal

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association
ISSN: 1365-277X
Titre abrégé: J Hum Nutr Diet
Pays: England
ID NLM: 8904840

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 23 4 2019
medline: 12 9 2020
entrez: 23 4 2019
Statut: ppublish

Résumé

The use of home parenteral nutrition (HPN) for palliative indications is increasing internationally and is the leading indication in some countries. Discharge on HPN can be complex in metabolically unstable patients and requires intestinal failure expertise. Between 2012 and 2018, we performed a retrospective analysis aiming to assess the impact of a novel remote discharge pathway for palliative HPN patients. This was evaluated using a quality improvement approach. One hundred and twenty-five patients with active malignancy [mean (range) age 58 (25-80) years] were referred to the intestinal failure unit (IFU) for remote discharge. Of 82 patients were discharged from the oncology Centre on HPN using the pathway. The remaining 43 patients either declined HPN or the Oncology team felt that the patient became too unwell for HPN or died prior to discharge. There was an increase in patients referred for remote discharge from 13 in 2012 to 43 in 2017. The mean number of days between receipt of referral by the IFU to discharge on HPN from the oncology centre reduced from 29.4 days to 10.1 days. Following remote discharge, the mean number of days on HPN was 215.9 days. Catheter-related blood stream infection rates in this cohort were very low at 0.169 per 1000 catheter days. This is the first study to demonstrate the remote safe, effective and rapid discharge of patients requiring palliative HPN between two hospital sites. This allows patients with a short prognosis more time in their desired location.

Sections du résumé

BACKGROUND
The use of home parenteral nutrition (HPN) for palliative indications is increasing internationally and is the leading indication in some countries. Discharge on HPN can be complex in metabolically unstable patients and requires intestinal failure expertise.
METHODS
Between 2012 and 2018, we performed a retrospective analysis aiming to assess the impact of a novel remote discharge pathway for palliative HPN patients. This was evaluated using a quality improvement approach.
RESULTS
One hundred and twenty-five patients with active malignancy [mean (range) age 58 (25-80) years] were referred to the intestinal failure unit (IFU) for remote discharge. Of 82 patients were discharged from the oncology Centre on HPN using the pathway. The remaining 43 patients either declined HPN or the Oncology team felt that the patient became too unwell for HPN or died prior to discharge. There was an increase in patients referred for remote discharge from 13 in 2012 to 43 in 2017. The mean number of days between receipt of referral by the IFU to discharge on HPN from the oncology centre reduced from 29.4 days to 10.1 days. Following remote discharge, the mean number of days on HPN was 215.9 days. Catheter-related blood stream infection rates in this cohort were very low at 0.169 per 1000 catheter days.
CONCLUSIONS
This is the first study to demonstrate the remote safe, effective and rapid discharge of patients requiring palliative HPN between two hospital sites. This allows patients with a short prognosis more time in their desired location.

Identifiants

pubmed: 31006921
doi: 10.1111/jhn.12650
doi:

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

492-500

Informations de copyright

© 2019 The British Dietetic Association Ltd.

Auteurs

A Bond (A)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

A Teubner (A)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

M Taylor (M)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

L Willbraham (L)

The Christie NHS Foundation Trust, Manchester, UK.

L Gillespie (L)

The Christie NHS Foundation Trust, Manchester, UK.

K Farrer (K)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

M McMahon (M)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

G Leahy (G)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

A Abraham (A)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

M Soop (M)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.

A R Clamp (AR)

The Christie NHS Foundation Trust, Manchester, UK.

J Hasan (J)

The Christie NHS Foundation Trust, Manchester, UK.

C Mitchell (C)

The Christie NHS Foundation Trust, Manchester, UK.

G C Jayson (GC)

The Christie NHS Foundation Trust, Manchester, UK.
The University of Manchester, Manchester, UK.

S Lal (S)

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.
The University of Manchester, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH